JP2019537619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537619A5 JP2019537619A5 JP2019538088A JP2019538088A JP2019537619A5 JP 2019537619 A5 JP2019537619 A5 JP 2019537619A5 JP 2019538088 A JP2019538088 A JP 2019538088A JP 2019538088 A JP2019538088 A JP 2019538088A JP 2019537619 A5 JP2019537619 A5 JP 2019537619A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- antibody
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400589P | 2016-09-27 | 2016-09-27 | |
| US62/400,589 | 2016-09-27 | ||
| US201662406727P | 2016-10-11 | 2016-10-11 | |
| US62/406,727 | 2016-10-11 | ||
| US201762480994P | 2017-04-03 | 2017-04-03 | |
| US62/480,994 | 2017-04-03 | ||
| US201762507580P | 2017-05-17 | 2017-05-17 | |
| US62/507,580 | 2017-05-17 | ||
| PCT/US2017/053370 WO2018064013A1 (en) | 2016-09-27 | 2017-09-26 | METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019537619A JP2019537619A (ja) | 2019-12-26 |
| JP2019537619A5 true JP2019537619A5 (https=) | 2020-11-12 |
Family
ID=66538296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538088A Pending JP2019537619A (ja) | 2016-09-27 | 2017-09-26 | β２−糖タンパク質１のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3519827A1 (https=) |
| JP (1) | JP2019537619A (https=) |
| KR (1) | KR20190057303A (https=) |
| CN (1) | CN109863402A (https=) |
| AU (1) | AU2017334698A1 (https=) |
| CA (1) | CA3037008A1 (https=) |
| MX (1) | MX2019003569A (https=) |
| WO (1) | WO2018064013A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11571459B2 (en) | 2017-04-03 | 2023-02-07 | Oncxerna Therapeutics, Inc. | Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents |
| US20200064353A1 (en) * | 2018-08-13 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Therapeutic Protein Selection in Simulated In Vivo Conditions |
| TW202535468A (zh) * | 2020-05-12 | 2025-09-16 | 瑞典商阿斯特捷利康公司 | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 |
| CN112698033A (zh) * | 2020-12-09 | 2021-04-23 | 复旦大学附属中山医院 | 一种血源性外泌体her2的检测方法及其应用 |
| CN114716547B (zh) * | 2022-05-18 | 2023-11-21 | 珠海丽禾医疗诊断产品有限公司 | 一种包括抗原结合结构域的结合蛋白及其生产方法和应用 |
| WO2024065243A1 (en) * | 2022-09-28 | 2024-04-04 | University Of Macau | Drug for treatment of breast cancer and application thereof |
| CN119555937B (zh) * | 2025-01-26 | 2025-05-20 | 杭州奥泰生物技术股份有限公司 | 一种犬虫媒病五联抗体检测卡及其制备方法和试剂盒 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| CA2333147C (en) | 1998-07-13 | 2012-02-07 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US7906115B2 (en) | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7572448B2 (en) | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
| AU2012201537B2 (en) * | 2002-07-15 | 2014-06-05 | Board Of Regents, The University Of Texas System | Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer |
| US7611704B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7247303B2 (en) | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
| CN101146826A (zh) | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| CA2705152C (en) | 2007-11-09 | 2016-10-11 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| CN106030304B (zh) | 2014-02-27 | 2018-02-06 | 得克萨斯大学体系董事会 | 用于分离外来体的方法和组合物 |
| RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
-
2017
- 2017-09-26 KR KR1020197008828A patent/KR20190057303A/ko not_active Ceased
- 2017-09-26 MX MX2019003569A patent/MX2019003569A/es unknown
- 2017-09-26 JP JP2019538088A patent/JP2019537619A/ja active Pending
- 2017-09-26 WO PCT/US2017/053370 patent/WO2018064013A1/en not_active Ceased
- 2017-09-26 AU AU2017334698A patent/AU2017334698A1/en not_active Abandoned
- 2017-09-26 CN CN201780058161.8A patent/CN109863402A/zh active Pending
- 2017-09-26 CA CA3037008A patent/CA3037008A1/en not_active Abandoned
- 2017-09-26 EP EP17791768.9A patent/EP3519827A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537619A5 (https=) | ||
| Hidalgo et al. | First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid tumors | |
| Wu et al. | Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway | |
| Otvos Jr et al. | Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer | |
| Wu et al. | Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF (V600E) mutant cancer cells | |
| ES2734673T3 (es) | Predicción de la sensibilidad farmacológica de tumores de pulmón basándose en identificaciones moleculares y genéticas | |
| Nikolaou et al. | The role of neurotensin and its receptors in non-gastrointestinal cancers: A review | |
| Mittal et al. | Recent advances in targeted therapy for glioblastoma | |
| AU2018287519A1 (en) | Il-1beta binding antibodies for use in treating cancer | |
| JP6381735B2 (ja) | 併用抗がん剤の感受性判定マーカー | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| CN115869325A (zh) | 化合物用于制备治疗kras突变癌症患者的药物的用途 | |
| CN117425515A (zh) | 用交变电场和曲妥珠单抗的组合进行治疗的组合物和方法 | |
| Park et al. | GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer | |
| CN112469391A (zh) | 包括chk1抑制剂的癌症的治疗方法 | |
| JP2023156343A (ja) | がん幹細胞の低減におけるｗｎｔ５ａペプチド | |
| JP2017535548A5 (https=) | ||
| Yuan et al. | Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma | |
| Deneka et al. | Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model | |
| KR20230004590A (ko) | 다형성 교모세포종에서의 abcb5 표적화 | |
| KR20250169564A (ko) | 암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정 | |
| Huhtala et al. | Biodistribution and antitumor effect of Cetuximab-targeted lentivirus | |
| Simeone et al. | A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600 BRAF mutation | |
| US20210154262A1 (en) | Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer | |
| Sugiyama et al. | Gli2 protein expression level is a feasible marker of ligand-dependent hedgehog activation in pancreatic neoplasms |